Clinical Trial

Trial Protocol ID IK930-001 *RIT*

Trial Description

A Phase 1, First-in-Human Study of IK-930, an Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors

View on ClinicalTrials.gov

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com or call us at 877-664-7724

Disease Types

Sponsor

  • Ikena Oncology

ClinicalTrials.gov NCT ID

  • NCT05228015